<DOC>
	<DOCNO>NCT00322608</DOCNO>
	<brief_summary>This Phase 1 clinical trial examine safety , pharmacokinetics pharmacodynamics escalate dos vascular disrupt agent NPI-2358 patient refractory solid tumor lymphoma . The formation new blood vessel ( angiogenesis ) important component tumor growth vascular disrupting agent intend target difference tumor blood vessel blood vessel normal tissue . NPI-2358 also see directly affect tumor cell .</brief_summary>
	<brief_title>Study Vascular Disrupting Agent NPI-2358 Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>ECOG performance status ≤ 2 Pathologically histologically confirm solid tumor malignancy Patients must candidate regimen know provide clinical benefit . All adverse event prior chemotherapy , surgery , radiotherapy , must resolve National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) ( v. 3.0 ) Grade ≤ 2 , except neurological toxicity must resolve Grade ≤ 1 . Adequate bone marrow reserve , hepatic renal function Signed informed consent Administration chemotherapy , biological , immunotherapy investigational agent ( therapeutic diagnostic ) within 21 day prior receipt study medication ( 6 week nitrosoureas mitomycin C ; 12 week radioimmunotherapy ) . Major surgery , diagnostic surgery , within 6 week first study drug administration . Radiotherapy within 4 week ( type radiation therapy exclude regardless interval since treatment ) . Significant cardiac history finding Underlying condition medication associate bleed diathesis Disorders associate significant vascular pathology Lung cancer central chest tumor Prior treatment vascular disruptive agent Seizure disorder require anticonvulsant therapy ; prior transient ischemic attack cerebrovascular accident Brain metastasis Severe chronic obstructive pulmonary disease ( COPD ) hypoxemia Active uncontrolled bacterial , viral , fungal infection , require systemic therapy Known infection human immunodeficiency virus ( HIV ) , active hepatitis A , B , C Patients prior hypersensitivity reaction product contain Solutol and/or propylene glycol Pregnant breastfeeding woman . Female patient must postmenopausal , surgically sterile must agree use acceptable method birth control . Female patient childbearing potential must negative serum pregnancy test . Male patient must surgically sterile agree use acceptable method contraception . Concurrent , active second malignancy patient receive therapy , exclude basal cell carcinoma skin carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Lymphomas</keyword>
</DOC>